Hiroshi Kagamu

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

Satoshi Watanabe, Junta Tanaka, Takeshi Ota et al. · BMC Cancer · 2011 · 392 citations · Full text

CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy

Hiroshi Kagamu, Shigehisa Kitano, Ou Yamaguchi et al. · Cancer Immunology Research · 2019 · 255 citations

Anti-pd-1 Therapy, Pd-1 Blockade, T-regulatory Cell +27

Megalin Blockade with Cilastatin Suppresses Drug-Induced Nephrotoxicity

Y Hori, Nobumasa Aoki, Shoji Kuwahara et al. · Journal of the American Society of Nephrology · 2017 · 141 citations · Full text

Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial

Koichi Takayama, Nobuyuki Katakami, Takuma Yokoyama et al. · Supportive Care in Cancer · 2016 · 140 citations · Full text

Reciprocal CD4+ T-Cell Balance of Effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ Regulatory T Cells in Small Cell Lung Cancer Reflects Disease Stage

K. Koyama, Hiroshi Kagamu, Satoru Miura et al. · Clinical Cancer Research · 2008 · 132 citations · Full text